LECTURE 6

Polymer Composite Materials in Sustained-Release Dosage Forms

Clinical Roles, Immobilization Chemistry, Release Kinetics, and Nanocomposite Systems

Lecture: acc.professor Kudaibergenova Bates Malikovna.

Lecture Overview: Plan, Aim & Key Tasks

Lecture Plan

1. Fundamentals: Polymer composites & extended release

2. Principles: Physical vs. chemical drug immobilization

3. Transport Models: Fickian diffusion & Higuchi kinetics

4. Matrices: Nanocomposites, hydrogels & microcapsules

5. Applications: Targeted therapy & smart stimuli-release

Lecture Aim

To evaluate the functional role of polymer composite systems in oral, parenteral, and implantable sustained-release dosage forms, establishing the physicochemical principles of drug immobilization, mass transport control, and targeted release profiles.

Key Learning Tasks

Define: Matrix composition & tortuosity factor

Differentiate: Entrapment, ionic & covalent binding

Derive: Korsmeyer-Peppas release exponent (n)

Analyze: Clay nanocomposites & stimuli hydrogels

Biomedical Advantage: Sustained-release composite formulations eliminate therapeutic concentration spikes, prolong plasma half-life, and maximize patient compliance.

Concept & Need for Sustained-Release Dosage Forms

Traditional immediate-release dosage forms produce fluctuating plasma concentrations, risking toxicity peaks and sub-therapeutic troughs.

Therapeutic Window Maintenance
Maintains active drug level steadily between Minimum Effective Concentration (MEC) and Minimum Toxic Concentration (MTC).

Reduced Dosing Frequency
Extends administration intervals from multiple daily doses to once-daily or monthly long-acting implants.

Localized & Targeted Delivery
Directs active therapeutic release to specific anatomical sites or biological tissues, minimizing systemic side effects.



Role & Synergies of Polymer Composite Systems

Multi-Phase Barrier Effect

Tortuosity Factor (τ): Increases effective path length by 3x–10x.

Blending polymers with inorganic nanofillers (clays, silica, carbon) creates tortuous diffusion pathways, retarding solvent ingress and drug egress.

Mechanical Integrity Control

Stability: Maintains dimensional stability during hydration.

Inorganic or secondary polymer phases prevent structural matrix collapse, swelling-induced disintegration, or early burst release.

Tunable Hydrophilicity

Tailored Release: Zero-order release profiles over weeks.

Combining hydrophilic (PVA, PEG, Alginate) with hydrophobic (PLA, PCL, Ethylcellulose) components tunes hydration velocity and erosion rate.

Composite Definition: A multi-component matrix where phase interactions yield release properties unattainable by any single constituent.

Principles of Active Molecule Immobilization

Classification of Immobilization Bonds

Therapeutic agent binding into polymer composites relies on physical entrapment, electrostatic/ionic pairing, or cleavable covalent attachment.

1. Physical Entrapment / Encapsulation
Passive steric inclusion within polymer mesh, pore networks, or core-shell micro-cavities.

2. Electrostatic & Ionic Interaction
Reversible polyelectrolyte complexation between oppositely charged polymer chains and ionically charged drugs.

3. Covalent Prodrug Conjugation
Chemical linkage via hydrolytically or enzymatically labile spacers (ester, amide, hydrazone bonds).

Key Parameter: Immobilization strength governs whether release is controlled by diffusion, erosion, or chemical cleavage.

Physical Immobilization Mechanisms

Steric Mesh Entrapment

Condition: When ξ ≈ r_h, diffusion is significantly hindered.

Active molecules are physically dispersed during polymer crosslinking. Mesh size (ξ) relative to hydrodynamic drug radius (r_h) determines mobility.

Porous Clay Adsorption

Sorption Capacity: High specific surface area (>200 m²/g).

Intercalation of drug molecules into inorganic layered silicates (Montmorillonite, Halloysite nanotubes) via van der Waals forces and hydrogen bonding.

Hydrophobic Core Solubilization

Efficiency: High loading capacity for BCS Class II drugs.

Poorly soluble hydrophobic drugs partition into the non-polar domains of amphiphilic block copolymer micellar composites (e.g., Pluronics, PEG-PLLA).

Advantage: Preserves the chemical structure and biological activity of sensitive protein/peptide drugs.

Ionic Immobilization & Polyelectrolyte Complexes

Polyelectrolyte Coacervation Mechanics

Oppositely charged polymers (e.g., cationic Chitosan and anionic Alginate or Carboxymethylcellulose) form ionically crosslinked complex networks that bind ionic therapeutics.

Ion-Exchange Mechanism
Drug release is triggered by competitive ion displacement in physiological saline solutions (Na+, Cl- ions).

pH-Dependent Binding Capacity
Protonation/deprotonation of carboxylic (-COOH) or amine (-NH2) groups alters net charge and release rate.

Crosslinked polystyrene sulfonate or divinylbenzene resins forming insoluble drug-resinate complexes for oral suspensions.

Clinical Example: Prolonged taste-masked pediatric liquid formulations and mucosal adhesives.

Covalent Immobilization & Polymer-Drug Conjugates

Ringsdorf Model Architecture

Linker Chemistry: Esters, hydrazones, disulfides, or peptidic substrates (GFLG).
Polymer backbone + Solubilizer domain + Cleavable Linker + Active Drug.

Cleavage Mechanisms

Enzymatic: Lysosomal Cathepsin B cleaves GFLG peptide spacers.

Acid-Labile: Endosomal pH (5.0–5.5) cleaves hydrazone/cis-aconityl bonds.

Redox-Responsive: Intracellular GSH cleaves disulfide (-S-S-) crosslinks.

EPR Effect: Polymer-drug conjugates (>30 kDa) passively accumulate in tumor tissue via Enhanced Permeability and Retention.

Diffusion-Controlled Release Kinetics

Fickian Diffusion Modeling

Mass flux (J) through a composite polymer membrane is proportional to the concentration gradient ($\partial C/\partial x$) according to Fick's First Law.

Higuchi Matrix Equation

$$Q = [D \cdot (2A - C_s) \cdot C_s \cdot t]^{0.5}$$

Where Q is cumulative drug released per unit area, D is diffusion coefficient, A is total drug loading, and C_s is drug solubility.

Reservoir vs. Matrix: Reservoir systems yield constant zero-order release; matrix systems exhibit square-root time decay.

Erosion-Controlled Release Mechanics

Surface-Eroding Matrices

Release Profile: Ideal zero-order constant release rate (dM/dt = k).
Polyanhydrides and poly(ortho esters). Water hydrolysis is faster than water penetration rate into the core.

Bulk-Eroding Matrices

Release Profile: Tri-phasic release (burst → lag phase → accelerated erosion release).
PLA, PGA, PLGA copolymers. Water diffuses rapidly throughout the whole composite volume before polymer chain scission occurs.

Korsmeyer-Peppas Power Law: $M_t / M_\infty = k \cdot t^n$ (where $n = 0.5$ indicates Fickian diffusion; $n = 1.0$ indicates Case II transport/erosion).

Swelling-Controlled Hydrogel Composite Systems

Glassy-to-Rubbery Phase Transition

Initial dry composite matrix exists in a glassy state with immobilized drug. Solvent penetration lowers glass transition temperature (Tg) below medium temperature, inducing polymer chain relaxation into a swollen rubbery gel.

Deborah Number (De) Governing Transport

$De = \lambda / \theta$

Ratio of characteristic polymer relaxation time (λ) to solvent diffusion time (θ). De ≈ 1 produces anomalous non-Fickian transport.

Moving boundary front separates dry glassy core from swollen gel layer, defining Case II transport kinetics.

Polymer Choices: HPMC, PVA, PEG, Polyacrylamide composites.

Polymer-Clay Nanocomposites in Drug Delivery

Montmorillonite (MMT)
2D Layered Aluminosilicate

Exfoliated silicate nanoplatelets form physical barriers, suppressing initial burst release and extending release up to 48 hours.

Halloysite Nanotubes (HNTs)
1D Hollow Tubular Clay

Tubular lumen (10–15 nm diameter) acts as a high-capacity reservoir for drug lumen entrapment and sustained tube end lumen elution.

Graphene Oxide (GO)
Functionalized Carbon Sheets

High π-π stacking binding capacity for aromatic anti-cancer drugs (Doxorubicin) combined with NIR-triggered release.

Structural States: Intercalated vs. Exfoliated nanostructures — Exfoliated silicate layers provide maximum barrier tortuosity.

Stimuli-Responsive Composite Systems ("Smart Delivery")

Environmentally Triggered Release

pH-Responsive Composites

Application: Targeted oral delivery of acid-labile biopharmaceuticals.

Eudragit (methacrylic acid copolymers) or Chitosan/PMAA composites. Protect drugs from gastric juice (pH 1.2) and dissolve specifically in intestinal pH (6.8–7.4).

Thermo-Responsive Composites

Application: Hyperthermia-triggered anti-cancer drug pulse release.

PNIPAAm-based composites exhibiting LCST (~32°C). De-swell above LCST to squeeze out entrapped therapeutics.

Magneto-Responsive Composites

Application: On-demand pulsed drug dosing controlled remotely.

Fe_3O_4 magnetic nanoparticles embedded inside hydrogel matrices. Alternating Magnetic Field (AMF) induces hyperthermic gel relaxation.

On-Demand Control: Shifts drug delivery from passive constant release to active self-regulated physiological dosing.

Microencapsulation & Core-Shell Composite Architecture

W/O/W Double Emulsion Evaporation

Water-in-oil-in-water double emulsion techniques yield PLGA/polyethylenimine composite microspheres encapsulating hydrophilic protein therapeutics.

> **Core-Shell Morphology Benefits**
> Hydrophobic polymer shell insulates fragile protein core from enzymatic degradation while dictating diffusional erosion velocity.

Clinical Application: Long-acting depot injections (e.g., Decapeptyl, Risperdal Consta).

Oral Sustained-Release Composite Matrix Tablets

Hydrophilic Matrix Tablets

Release Control: Viscosity grade (HPMC K100M) dictates release duration.

HPMC (Hydroxypropyl methylcellulose) + NaCMC blends. Upon GI fluid contact, polymer rapidly hydrates forming a gel layer that controls water entry and drug elution.

Lipid/Insoluble Polymer Matrix

Mechanism: Pore-former additives (PVP) modulate channel porosity.

Ethylcellulose + Hydrogenated Vegetable Oil composites. Inert non-swelling porous matrix where drug dissolves and diffuses through fluid-filled tortuous pores.

Gastroretentive Systems: Low-density floating composite tablets (HPMC + $NaHCO_3$) remaining in the stomach for 8+ hours.

Implantable Polymer Composite Drug Delivery Systems

Subdermal Rod Implants
EVA / Silicone Matrices

Non-biodegradable composite rods (Norplant, Implanon) delivering contraceptive steroids continuously for 3 to 5 years.

Biodegradable Bone Wafers
Polyanhydride / CPP-SA

Gliadel Wafer implanted in brain resection cavities eluting Carmustine (BCNU) locally over 2–3 weeks to eradicate residual tumor cells.

In-Situ Forming Implants
PLGA in NMP Solvent (Atrigel)

Injectable liquid solution precipitates in vivo upon organic solvent diffusion, forming a solid subcutaneous drug depot.

Biocompatibility Criterion: Implantable matrices must produce zero fibrous capsule encapsulation that would impede drug diffusion.

Composite Electrospun Nanofibers in Wound Healing

High Surface Area-to-Volume Ratio

Electrospinning polymer blends (PCL/Gelatin, PLA/Chitosan) produces non-woven nanofibrous mats (fiber diameters 50–500 nm) mimicking ECM structure.

Coaxial Electrospinning Core-Shell Fibers

Dual-needle nozzle encapsulates antibiotic/growth factor core within protective polymer shell, providing biphasic immediate hemostasis followed by 14-day sustained release.

Nanofiber Porosity

High interconnected porosity (>80%) permits gas exchange while preventing bacterial penetration into skin wounds.

Therapeutic Payloads: Silver nanoparticles, VEGF growth factors, NSAIDs, and broad-spectrum antibiotics.

In-Vitro Dissolution & Release Testing Standards

USP Apparatus 1 & 2

Basket and Paddle apparatus operated at 37±0.5°C in simulated gastric (pH 1.2) or intestinal (pH 6.8) fluids for oral matrix tablets.

USP Apparatus 4 (Flow-Through Cell)

Continuous fluid flow through cell ideal for poorly soluble drugs, microparticles, and non-disintegrating composite implants.

Franz Diffusion Cells

Vertical membrane diffusion cell measuring transdermal and mucosal drug release across composite hydrogels or patches.

Sink Conditions: Dissolution medium volume must be at least 3 to 10 times larger than the drug saturation volume ($C < 0.2\ C_s$).

In-Vitro / In-Vivo Correlation (IVIVC)

Level A Correlation (FDA Gold Standard)

A point-to-point mathematical relationship between in-vitro dissolution rate and in-vivo absorption rate across the entire release time course.

> **Wagner-Nelson / Loo-Riegelman Deconvolution**
> Mathematical algorithms converting plasma drug concentration-time curves into cumulative systemic absorption fraction.

BCS Class Impact: High solubility / low permeability (Class III) drugs demand precise composite barrier design.

Polymer Composite Systems: Clinical Pros & Cons

Therapeutic Advantages

1. **Plasma Level Stability:** Prevents peak-and-valley concentration swings.
2. **Reduced Toxicity:** Minimizes off-target organ exposure.
3. **High Protection:** Protects sensitive peptide/protein drugs from enzymatic cleavage.
4. **Tailored Kinetics:** Enables zero-order or pulse-responsive drug release profiles.

Technical Limitations

1. **Dose Dumping Risk:** Sudden structural failure causes catastrophic drug discharge.
2. **Removal Necessity:** Non-biodegradable implants require surgical retrieval.
3. **High Production Cost:** Complex multi-step nano-fabrication processes.
4. **Stability Issues:** Polymer degradation or phase separation during long-term storage.

Quality by Design (QbD): Requires strict critical quality attribute (CQA) controls over composite particle size and matrix porosity.

Biocompatibility & Safety of Composite Carrier Residues

Nanoparticle Accumulation

Non-degradable inorganic nanofillers (silica, GO, carbon nanotubes) can accumulate in Reticuloendothelial System (RES) organs (liver, spleen).

Acid Microenvironment

PLGA/PGA bulk erosion generates lactic and glycolic acid accumulation inside microspheres, dropping internal pH to ~2.0 and denaturing proteins.

Residual Solvent Toxicity

Traces of Class 2 solvents (DCM, NMP) used during solvent evaporation microencapsulation must meet ICH Q3C limits (<600 ppm).

Formulation Strategy: Incorporating basic inorganic salts ($Mg(OH)_2$, $CaCO_3$) into PLGA composites neutralizes local acidic degradation products.

Regulatory Standards & FDA Approval Considerations

FDA Inactive Ingredient Database (IID)

Novel Excipients: Require standalone toxicological evaluation dossiers.

Polymer composite excipients must be listed in the IID for the specific route of administration at or below approved maximum potency levels.

Combination Products (21 CFR Part 3)

Approval Route: NDA 505(b)(2) pathway utilized for novel sustained-release formulations of approved APIs.

Drug-eluting stents and implantable composite devices are classified based on their Primary Mode of Action (PMOA), determining FDA CDER vs. CDRH jurisdiction.

Global Standards: Compliance with ICH Q8 (Pharmaceutical Development) and ISO 10993 biocompatibility testing.

Future Horizons: 4D Printed & Theranostic Composites

4D Printed Shape-Morphing Delivery Devices

3D printed polymer composites that alter their geometry over time in response to physiological triggers, expanding inside the stomach for prolonged gastric retention.

Theranostic Composites: Integrating MRI contrast agents (iron oxide) with drugs for simultaneous real-time release imaging.

RNA/CRISPR Nanocomposites: Lipid-polymer hybrid nanoparticles delivering mRNA with extended intracellular release.

Bio-Inspired Mussel Adhesives: Catechol-functionalized composite hydrogels for long-acting mucosal adhesion.

Clinical Vision: Fully autonomous, closed-loop responsive composite systems providing personalized drug dosing.

Summary: Principles of Polymer Composites in Drug Delivery

01

Functional Role

Composites increase tortuosity, maintain mechanical stability, and tailor matrix hydration to achieve steady therapeutic plasma levels.

02

Immobilization Pathways

Steric entrapment, polyelectrolyte ionic complexation, and cleavable covalent prodrug conjugation dictate release mechanisms.

03

Transport Dynamics

Mass transport operates via Fickian matrix diffusion, bio-erosion cleavage, or swelling-controlled phase transitions.

Core Takeaway: Integrating polymer composite chemistry with physical transport modeling enables precise, safer, long-acting pharmaceutical dosage forms.

Thank You for Your Attention

acc.professor Kudaibergenova Bates Malikovna.